Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2014 Jul;29(7):1021-4.
doi: 10.3346/jkms.2014.29.7.1021. Epub 2014 Jul 11.

The significance of clinical and laboratory features in the diagnosis of glycogen storage disease type v: a case report

Affiliations
Case Reports

The significance of clinical and laboratory features in the diagnosis of glycogen storage disease type v: a case report

Hyung Jun Park et al. J Korean Med Sci. 2014 Jul.

Abstract

Glycogen storage disease type V (GSD-V) is the most common disorder of muscle glycogenosis with characteristic clinical and laboratory findings. A 32-yr-old woman complained of exercise intolerance and myoglobulinuria since early adolescence. She reported several episodes of second-wind phenomenon. Physical examination did not show any neurological abnormality, including fixed muscle weakness or atrophy. Serum creatine kinase level was 1,161 IU/L at rest. The result of the non-ischemic forearm exercise test was compatible with GSD-V. Mutation analysis identified the compound heterozygous mutations of the PYGM, p.D510fs and p.F710del, which has not yet been reported in Korea. The present case recognizes that detail clinical and laboratory analysis is the first step in the diagnosis of GSD-V.

Keywords: Glycogen Storage Disease Type V; McArdle's Disease; Phosphorylase, Glycogen, Muscle (PYGM).

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Pedigree and Sequencing chromatograms in Korean patient with PYGM mutations. (A) Pedigree of a family with glycogen storage disease type V (GSD-V). Arrow indicates the proband, whose DNA was used for direct sequencing of PYGM. Filled symbol indicate affected member. (B) Sequencing chromatograms of PYGM mutations. One allele had a frameshift mutation of c.1531delG (p.D510fs) in exon 13 and the other allele had a deletion mutation of c.2128_2130delTTC (p.F710del) in exon 17.
Fig. 2
Fig. 2
Non-ischemic forearm exercise test in a patient with GSD-V. The non-ischemic forearm exercise test showed no increase in venous lactate level with a normal increase in ammonia.

Similar articles

Cited by

References

    1. Vieitez I, Teijeira S, Fernandez JM, San Millan B, Miranda S, Ortolano S, Louis S, Laforet P, Navarro C. Molecular and clinical study of McArdle's disease in a cohort of 123 European patients: identification of 20 novel mutations. Neuromuscul Disord. 2011;21:817–823. - PubMed
    1. Dimaur S, Andreu AL, Bruno C, Hadjigeorgiou GM. Myophosphorylase deficiency (glycogenosis type V; McArdle disease) Curr Mol Med. 2002;2:189–196. - PubMed
    1. Haller RG. Treatment of McArdle disease. Arch Neurol. 2000;57:923–924. - PubMed
    1. Lucia A, Ruiz JR, Santalla A, Nogales-Gadea G, Rubio JC, García-Consuegra I, Cabello A, Pérez M, Teijeira S, Vieitez I, et al. Genotypic and phenotypic features of McArdle disease: insights from the Spanish national registry. J Neurol Neurosurg Psychiatry. 2012;83:322–328. - PubMed
    1. Sohn EH, Kim HS, Lee AY, Fukuda T, Sugie H, Kim DS. A novel PYGM mutation in a Korean patient with McArdle disease: the role of nonsense-mediated mRNA decay. Neuromuscul Disord. 2008;18:886–889. - PubMed

Publication types

Substances